Last reviewed · How we verify
NCT07108647
In-Season Prevalence and Management of Hip and Groin Injuries in Competitive Athletes
Phase 1 trial testing Progressive Hip Strengthening Program in Femoroacetabular Impingement Syndrome in 30 participants. Not yet recruiting.
1 September 2026
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 August 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2026 |
Drugs / interventions tested
- Progressive Hip Strengthening Program
- Progressive Muscle Relaxation
Conditions studied
- Femoroacetabular Impingement Syndrome — all drugs for Femoroacetabular Impingement Syndrome →
Sponsor
University of Calgary
Who can join
Adults 14 to 40, any sex, with Femoroacetabular Impingement Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is focused on helping athletes with a common hip condition called femoroacetabular impingement (FAI) syndrome. FAI syndrome occurs when abnormal bone shapes around the hip joint cause friction during movement, leading to pain, reduced performance, and, over time, more serious injury. While this issue is well-studied in male professional athletes, little is known about how it affects female and collegiate athletes, or how to prevent it from worsening. In this study, athletes diagnosed with FAI syndrome will participate in a 12-week in-season exercise program designed to reduce pain, improve hip strength and movement, and help prevent further injury-all while continuing their regular sports training. Participants will be randomly assigned to either: * An exercise group (receiving the intervention), or * A time-and-attention control group (regular check-ins and education). At the end of the study, the control group will have the option to access the exercise program. The study will track changes in pain, physical performance, injury recurrence, and athlete satisfaction with the program. This research aims to improve how we manage hip injuries in athletes and help keep them active during the competitive season.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07108647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Femoroacetabular Impingement Syndrome
Currently open trials in the same condition.
- NCT06653985 — Intra-articular Corticosteroid With Hyaluronic Acid Plus Physiotherapy for Hip Pathologies (NON-OP HIP) · NA · recruiting
- NCT06845735 — Absorbable vs Non-Absorbable Sutures for Hip Capsular Closure · NA · recruiting
- NCT05927935 — First-line Treatment for Femoroacetabular Impingement Syndrome · NA · active not recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07108647 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07108647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing